Orthopaedic treatment is shifting as regenerative therapies focus on biological healing rather than mechanical repair. Firstpost talked to expert to know how PRP, stem cells and biologics are being used for joint pain, sports injuries and osteoarthritis.
Orthopaedic care is undergoing a paradigm shift, moving beyond the “hardware and hinges” approach of traditional surgery toward regenerative medicine. By leveraging the body’s own biological toolkit including PRP, stem cell therapies and advanced biologics, specialists are now able to repair damaged cartilage and ligaments from within.
This “biological revolution” does more than just mask symptoms; it preserves native joint structures and offers a clinically proven path to delay invasive replacements. When paired with precision medicine, these therapies provide a potent alternative for patients seeking to restore function, eliminate chronic pain and bypass the operating table.
Firstpost talked to Dr. Sorabh Garg, Consultant at Apollo Spectra Hospital (Delhi) to understand how regenerative medicine is changing the way orthopaedic conditions are treated, the science behind PRP and stem cell therapies, which patients benefit the most and why these biologic treatments could help delay surgery, reduce long-term pain medication use and improve quality of life in both sports injuries and age-related musculoskeletal disorders.
How is regenerative medicine changing orthopaedic care compared to traditional repair methods?
Dr Garg: Orthopaedic traditional treatments are focused on mechanical repair leading to reduction in pain, performing replacement of damaged structure with the help of surgery. Emerging shift is also represented by regenerative medicine. It also helps to stimulate own healing mechanism of body along with fixing or healing those tissues that are damaged and regenerate specific tissues such as cartilage, tendons, ligaments, and bone. This approach also allows Pain and regenerative specialist to move from symptom management with aim to support biological healing restoration, and helps in preserving native joint structures in selected patients and making delay invasive procedures by many years in them.
How do regenerative therapies help the body heal itself in conditions like osteoarthritis or cartilage degeneration?
Dr Garg: In some degenerative condition, such as osteoarthritis or injury in ligaments, the main problem is the breakdown of tissue well combined with the reduction in capacity of healing. Working of regenerative modalities depends upon those substances that are biologically active such as those factors which are related to growth. Regenerative cell plays a good role in modulating the inflammation, stimulate cellular repair and enhance regeneration of injured tissues as well.
What role do PRP, stem cell, and biologic therapies play in delaying or avoiding joint replacement surgery?
Dr Garg: Platelet-Rich Plasma (PRP), stem cell therapies, and biologics are those kinds of medical treatments that have shown great result in reduction of pain, improving function of joint and enhance the quality of tissues that are present in body. These treatments can also delay the need for joint replacement surgery by addressing the challenge of inflammation and promoting repair at an early stage. Those patients who are young this means preserving their natural joint for longer period of time while maintain quality of life as well. PRP in particular less useful in joints but it has a good effects on muscles and tendon injuries with super concentrations.
Which patients benefit most, and at what stage is regenerative medicine most effective?
Dr Garg: In patients, regenerative medicine is most effective with early to moderate disease, where structural damage is present but not irreversible. Some ideal candidate in the same include individuals with early osteoarthritis, partial ligament or tendon injuries, cartilage wear, sports injuries, and patients experiencing chronic pain despite of conservative care as well. While advanced degeneration often require surgery, regenerative treatments can play a good supportive role in later stages by ultimately reducing the pain and improving functioning as well.
Dr Garg: Regenerative therapies help to accurate the healing, reducing downtime and lower the risk of multiple surgeries by improving the quality of life rather than just reducing symptoms. In those Musculoskeletal disorders, which are related to age, patients often experience improvement in mobility, reduced stiffness, and better control of pain, enabling them to stay active for long period of time. Most importantly, these treatments help elderly patients to avoid or postpone surgery which can carry higher risks in this population.
Can regenerative medicine reduce dependence on pain medications in chronic orthopaedic conditions?
Dr Garg: One of the most important advantages of regenerative medicine is its potential to eliminate or significantly lowering down the dependence on painkillers which also include NSAIDs and opioids. By addressing the inflammation and promoting the repair of tissue at the source, patients usually experience well sustained relief from pain. This kind of shift is significant as the risk is linked with the use of chronic medication such as gastrointestinal issues, renal damage, and dependency.
What recent scientific advancement are improving the safety and predictability of regenerative treatments today?
Dr Garg: Treatments outcomes can be improved by making advancements in cell processing, imaging guidance, biomarker research, and standardisation of protocols. Some other factors such as high quality PRP preparation, technique related to stem cell isolation and better selection of patients have made regenerative therapies more safe, reproducible, and clinically dependable.
Do you see regenerative medicine becoming a mainstream first-line treatment in orthopaedic- related problems and what challenges still need to be addressed for wider adoption?
Dr Garg: Definitely yes regenerative medicine is moving steadily towards the mainstream, early line use of same in orthopaedics, especially for the mild to moderate diseases and injuries caused in sports. Its role will also get expand as standardised protocols and long-term outcome data get strengthen. Key challenges of the same usually include patient selection, regulatory clarity, cost accessibility, and managing expectations. Wider adoption also depends on various factors such as robust science, clinician training, and clear guidelines that clearly defines where regeneration truly outperforms conventional care.
End of Article